This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma.
- Investigator
- Ashley Ghiaseddin
- Ages
- 18 Years - 80 Years
- Sexes
- All
Update your location to show providers, locations, and services closest to you.
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma.
This is a prospective, multi-center, randomized, controlled, patient* and evaluator-blinded study comparing treatment with the CardiAMP cell therapy to a sham control treatment. A roll-in phase with a maximum of 10 subjects may occur.